Design of 7-amino-6-chloro-3H-imidazo[4,5-b]pyridine scaffold from 5-chloro-2,4-diaminopyrimidine pharmacophore: identification of potent inhibitors of anaplastic lymphoma kinase
暂无分享,去创建一个
A. Ghose | B. Dorsey | T. Angeles | Mark S. Albom | G. R. Ott | Jason C. Wagner | K. Learn | Zeqi Huang | W. Wan | M. Cheng
[1] H. Sakamoto,et al. Design and synthesis of a highly selective, orally active and potent anaplastic lymphoma kinase inhibitor (CH5424802). , 2012, Bioorganic & medicinal chemistry.
[2] A. Ghose,et al. Design, synthesis, and anaplastic lymphoma kinase (ALK) inhibitory activity for a novel series of 2,4,8,22-tetraazatetracyclo[14.3.1.1³,⁷.1⁹,¹³]docosa-1(20),3(22),4,6,9(21),10,12,16,18-nonaene macrocycles. , 2012, Journal of medicinal chemistry.
[3] D. Gingrich,et al. Development and Scale-Up of an Optimized Route to the ALK Inhibitor CEP-28122 , 2012 .
[4] G. Inghirami,et al. CEP-28122, a Highly Potent and Selective Orally Active Inhibitor of Anaplastic Lymphoma Kinase with Antitumor Activity in Experimental Models of Human Cancers , 2011, Molecular Cancer Therapeutics.
[5] M. Yazdanian,et al. 2,7-Disubstituted-pyrrolotriazine kinase inhibitors with an unusually high degree of reactive metabolite formation. , 2011, Chemical research in toxicology.
[6] A. Ghose,et al. 2,7-disubstituted-pyrrolo[2,1-f][1,2,4]triazines: new variant of an old template and application to the discovery of anaplastic lymphoma kinase (ALK) inhibitors with in vivo antitumor activity. , 2011, Journal of medicinal chemistry.
[7] J. Christensen,et al. Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). , 2011, Journal of medicinal chemistry.
[8] Andrew V. Anzalone,et al. Discovery of a potent inhibitor of anaplastic lymphoma kinase with in vivo antitumor activity. , 2010, ACS medicinal chemistry letters.
[9] P. Workman,et al. Imidazo[4,5-b]pyridine derivatives as inhibitors of Aurora kinases: lead optimization studies toward the identification of an orally bioavailable preclinical development candidate. , 2010, Journal of medicinal chemistry.
[10] G. R. Ott,et al. Anaplastic lymphoma kinase as a therapeutic target in anaplastic large cell lymphoma, non-small cell lung cancer and neuroblastoma. , 2010, Anti-cancer agents in medicinal chemistry.
[11] A. Look,et al. Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy , 2009, Expert review of anticancer therapy.
[12] J. A. Kumar,et al. Efficient and Inexpensive Synthesis of Benzimidazoles and Quinoxalines , 2008 .
[13] Zheng Yang,et al. Discovery and evaluation of 4-(2-(4-chloro-1H-pyrazol-1-yl)ethylamino)-3-(6-(1-(3-fluoropropyl)piperidin-4-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one (BMS-695735), an orally efficacious inhibitor of insulin-like growth factor-1 receptor kinase with broad spectrum in vivo antitumor activ , 2008, Journal of medicinal chemistry.
[14] Rongshi Li,et al. Development of anaplastic lymphoma kinase (ALK) small‐molecule inhibitors for cancer therapy , 2008, Medicinal research reviews.
[15] P. Workman,et al. Hit generation and exploration: imidazo[4,5-b]pyridine derivatives as inhibitors of Aurora kinases. , 2007, Bioorganic & medicinal chemistry letters.
[16] W. Yung,et al. Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo , 2007, Molecular Cancer Therapeutics.
[17] Peter G. Schultz,et al. Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK , 2007, Proceedings of the National Academy of Sciences.
[18] Mindy I. Davis,et al. A quantitative analysis of kinase inhibitor selectivity , 2008, Nature Biotechnology.